Background and Objective: GLP-1RAs including dulaglutide (DU) are recommended as 1st injectable therapy in T2D patients after oral antihyperglycemic medicine (OAM) failure. Efficacy and safety of DU have been studied when adding on OAMs, but not in Chinese population discontinued from OAM. This is the first post-hoc analysis to evaluate the efficacy and safety of DU in Chinese T2D patients discontinued from OAM and started with once weekly DU.
Methods: A total of 292 Chinese patients who discontinued from OAM monotherapy in AWARD-CHN1 study (NCT01644500) were included in this post-hoc analysis as modified intent-to-treat (mITT) population.
Results: Overall, the mITT population had mean age of 55.0 years, with 5.5 years’ mean duration of T2D at baseline. Previous OAM treatment included metformin, acarbose, sulfonylureas, and meglitinides. Table 1 summarized the efficacy and safety outcomes at Week 26. DU 1.5 mg was superior to glimepiride for HbA1c and body weight reduction. Greater improvement in beta cell function was observed for both DU groups, along with fewer hypoglycemia events. The most common adverse events for DU were gastrointestinal in nature, including diarrhea, abdominal distension, vomiting and nausea.
Conclusion: DU is effective and safe for Chinese T2D patients discontinued from OAM and can further improve glucose control and protect beta cell function compared to glimepiride.
Y. Li: None. B. Zhang: Employee; Self; Eli Lilly and Company. S. Liu: Employee; Self; Eli Lilly and Company.
